Acutaas Chemicals Management Change
Acutaas Chemicals appointed Dr. Ashish Kumar Pandey as AVP Operations (Cluster Head, Units 2 & 3) and designated as SMP from November 2, 2026. Two existing GMs ceased to be SMP but continue in the company.
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
49 announcements with these filters
Acutaas Chemicals appointed Dr. Ashish Kumar Pandey as AVP Operations (Cluster Head, Units 2 & 3) and designated as SMP from November 2, 2026. Two existing GMs ceased to be SMP but continue in the company.
Acutaas reports high-growth Q2 fueled by pharma intermediates and CDMO scaling, despite commodity chemical phase-outs.
Q2 FY27 revenue ₹4,369 Mn (+42.7% YoY), EBITDA ₹1,760 Mn (+84.6%, 40.3% margin), PAT ₹1,231 Mn (+71.4%). FY27 revenue guidance raised; South Korea semiconductor-chemicals facility inaugurated.
Q2 FY27 revenue rose 42.7% YoY to ₹4,369 mn; PAT up 71.4% to ₹1,231 mn. Guidance raised to 30% revenue growth and 38-40% EBITDA margin.
Acutaas Chemicals Ltd reported revenue from operations of ₹436.9 Cr (+42.7% YoY) and net profit of ₹123.1 Cr (+71.2% YoY) for Q2 FY27.
Acutaas Chemicals' board approved Q2 and half-year FY2027 unaudited results. The board meeting closed with no other material transaction disclosed.
Acutaas Chemicals scheduled its board meeting for October 27, 2026, to approve Q2 and H1 FY27 unaudited results. No financial figures or decisions are reported, only the meeting date and agenda.
Acutaas Chemicals completed the acquisition of Enchem Ami Organics, making it a wholly owned subsidiary. This share transfer transaction was completed for ₹0.01 Crore.
Acutaas Chemicals acquired a 100% stake in Enchem Ami Organics from its subsidiary, making it a direct wholly-owned subsidiary. No monetary value was disclosed for this transfer.
Acutaas Chemicals Ltd has submitted its quarterly shareholding pattern for the period ended September 30, 2026. This disclosure provides a detailed breakdown of equity ownership.
Designated Person Hemant Mahendabhai Patel pledged 1,000 equity shares of Acutaas Chemicals Ltd worth Rs. 0.33 Crore, as disclosed in the Regulation 7(2) PIT filing.
Acutaas Chemicals Limited has announced the re-appointment of Ram Mohan Lokhande as Executive Director and Anita Bandyopadhyay as Non-Executive Independent Director for a 60-month term.
Acutaas Chemicals will acquire 100% of Enchem Ami Organics Private Limited for Rs. 1 Lakh, making it a wholly owned subsidiary.
Acutaas Chemicals will acquire 100% equity stake in step-down subsidiary Enchem Ami Organics for Rs. 1 Lakh, making it a direct wholly-owned subsidiary.
Acutaas Chemicals Limited conducted its 19th Annual General Meeting on September 24, 2026, where shareholders transacted various ordinary and special business items.
Acutaas Chemicals Limited has received a patent from the Indian Patent Office for a process to prepare 2,4-dimethylthiophenol. The company now holds 11 patents.
Acutaas Chemicals Limited inaugurated a new state-of-the-art Pilot Plant at Unit 1 in Sachin, Surat. The facility supports R&D for high potency active pharmaceutical ingredients.
Acutaas Chemicals Limited has set September 17, 2026, as the record date for its final dividend of Rs. 2.50 per share for FY 2025-26.
Acutaas Chemicals Limited has submitted its Business Responsibility and Sustainability Report for the financial year 2025-26. This filing complies with the SEBI LODR regulations.
Acutaas Chemicals Limited has submitted its Annual Report for the financial year 2025-26. The document contains comprehensive performance details, strategic updates, and statutory reports.
Acutaas Chemicals Limited has issued a notice for its 19th Annual General Meeting on September 24, 2026, to consider financial statements, director appointments, and related-party transaction limits.
Acutaas Chemicals' subsidiary, Indichem Inc., inaugurated its semiconductor materials manufacturing plant in South Korea. The new facility enhances the company's semiconductor supply chain capabilities.
Acutaas Chemicals approved a Rs. 212 Crore capital expenditure plan for a new manufacturing plant in Gujarat. The Board also announced the upcoming 19th AGM.
Acutaas Chemicals received approval for incentives under the Electronics Components Manufacturing Scheme. The company expects benefits of 25% on an eligible investment of ₹119.12 Crore.
Acutaas Chemicals Limited received MeitY approval for an incentive package under the Electronics Components Manufacturing Scheme. The company is expected to receive incentives up to 25% of Rs.119.12 Crore.
Acutaas Chemicals delivered a robust Q1 FY27 with 59.1% revenue growth, fueled by strong CDMO and Advanced Pharmaceutical Intermediates (API) performance.
Acutaas Chemicals delivered strong Q1 FY27 results with 59% YoY revenue growth. Management is focused on scaling high-margin Pharma Intermediates and CDMO segments while maintaining operational efficiencies.
Acutaas Chemicals reported Q1 FY27 revenue of ₹329.7 crore and PAT of ₹75 crore. Revenue grew 59.1% YoY with PAT margins at 22.7%.
Acutaas Chemicals Ltd reported revenue from operations of ₹329.7 Cr (+59.1% YoY) and net profit of ₹75 Cr (+70.5% YoY) for Q1 FY27.
Acutaas Chemicals approved its unaudited standalone and consolidated financial results for the first quarter ended June 30, 2026. The board meeting concluded on July 24, 2026.